Wellfully (DB:L6Y) - Stock Price, News & Analysis

L6Y Stock Overview

Wellfully Limited, together with its subsidiaries, focuses on the development and commercialization of Dermaportation and ETP transdermal drug delivery technologies. More details

L6Y fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Earnings have declined by 37.1% per year over past 5 years

Does not have a meaningful market cap (€1M)

Negative shareholders equity

Shares are highly illiquid

+ 3 more risks

Wellfully Limited Competitors

Valeo Pharma

DB:VP2

€493.4k

Biofrontera

XTRA:B8FK

€16.4m

SynBiotic

DUSE:SBX

€27.9m

Cantourage Group

XTRA:HIGH

€55.6m

Price History & Performance

Summary of all time highs, changes and price drops for Wellfully
Historical stock prices
Current Share Price	AU$0.0005
52 Week High	AU$0.016
52 Week Low	AU$0.0005
Beta	-0.91
11 Month Change	0%
3 Month Change	0%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-94.95%

Recent updates

Shareholder Returns

	L6Y	DE Pharmaceuticals	DE Market
7D	0%	-5.0%	-1.3%
1Y	n/a	-22.0%	7.4%

Return vs Industry: Insufficient data to determine how L6Y performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how L6Y performed against the German Market.

Price Volatility

Is L6Y's price volatile compared to industry and market?
L6Y volatility
L6Y Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: L6Y has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine L6Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1992	n/a	Paul Peros	www.wellfully.net

Wellfully Limited, together with its subsidiaries, focuses on the development and commercialization of Dermaportation and ETP transdermal drug delivery technologies. It operates in two segments, Dermaportation Drug Delivery Technology and Devices. The company is also involved in the industrialization and supply-chain support for its existing product ranges; and sale and marketing of its own brands REDUIT and SWISSWELL, as well as third-party collaborations.

Wellfully Limited Fundamentals Summary

How do Wellfully's earnings and revenue compare to its market cap?
L6Y fundamental statistics
Market cap	€886.36k
Earnings (TTM)	-€4.68m
Revenue (TTM)	€997.10k

0.9x

P/S Ratio

-0.2x

P/E Ratio

Is L6Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
L6Y income statement (TTM)
Revenue	AU$1.66m
Cost of Revenue	AU$1.86m
Gross Profit	-AU$200.41k
Other Expenses	AU$7.60m
Earnings	-AU$7.80m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.016
Gross Margin	-12.05%
Net Profit Margin	-469.00%
Debt/Equity Ratio	-98.7%

How did L6Y perform over the long term?

See historical performance and comparison

Wellfully DB:L6Y Stock Report